サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1634211

性感染症（STD）診断薬の世界市場 - 2025年～2033年

Global Sexually Transmitted Diseases (STD) Diagnostics Market - 2025 - 2033

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
性感染症（STD）診断薬の世界市場 - 2025年～2033年
出版日: 2025年01月13日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

性感染症（STD）診断薬の世界市場は、2024年に106億米ドルに達し、2033年には194億米ドルに達すると予測され、予測期間2025年～2033年のCAGRは7.1%で成長します。

性感染症（STD）診断薬は、個人における性感染症（STI）の検出、同定、確認に使用される医療プロセスおよび技術を指します。これらの病気は主に性的接触によって感染し、細菌、ウイルス、寄生虫によって引き起こされます。STD診断には、検査室での検査、臨床評価、スクリーニングなど幅広い方法が含まれ、症状が現れる前の初期段階で感染症を検出することで、タイムリーな治療を可能にし、他者へのトランスミッションのリスクを低減します。

性感染症（STD）診断薬の需要は、性の健康に対する意識の高まりから診断技術の進歩に至るまで、様々な要因によって牽引されています。例えば、WHOの推計によると、2020年にはトリコモナス（1億5,600万人）、淋病（8,200万人）、梅毒（710万人）、クラミジア（1億2,900万人）の4つのSTIのいずれかに新たに感染するケースが3億7,400万件発生します。推定3億人の女性が、男性と性交渉を持つ男性の肛門がんや子宮頸がんの主な原因であるHPVに感染しています。こうした性病の増加は、性病診断薬の需要を増大させる。

市場力学：

促進要因と抑制要因

STD自己診断の進歩が進む

STD自己診断における進歩の高まりは、性感染症（STD）診断薬市場の成長を大きく後押ししており、予測期間中も市場を牽引するとみられます。性病の自己診断キットを使えば、ヘルスケア専門家に頼ることなく自宅で検査ができるため、より便利でプライベートな検査が可能になります。この動向は、STD検査に関連するスティグマを軽減する上で特に重要です。

例えば、2024年8月、ノバスコシア州は性感染症の無料自宅検査を提供する予定であり、これは重要なセクシャルヘルスケアへの障壁を減らすための重要な一歩である、と州エイズ連合の代表は言います。

さらに、2023年6月、ライフセル・インターナショナル社は、患者が自宅のプライバシーで細胞スワブや組織サンプルを採取できる検査キットを発売しました。この検査キットは、女性の子宮頸がんの原因となるヒトパピローマウイルス（HPV）や、梅毒や淋病などの性感染症の検出に使用できます。

最新の自己診断検査は、迅速な結果が得られるように設計されており、これが市場の重要な促進要因となっています。ユーザーは20分から1時間で検査結果を得ることができ、即答を求める人々にとってより魅力的なものとなっています。例えば、OraQuickは、検査機器を必要とせず、20分で結果が出るHIV迅速検査を提供しています。このような検査の速さと手軽さが、人気の高まりに寄与しています。

限られた認識と教育

性感染症（STD）診断薬市場の成長にとって、認識と教育が限定的であることが大きな障壁となっています。診断技術の進歩や検査オプションの増加にもかかわらず、STD検査の重要性に対する不十分な理解や性の健康に関する教育不足が、診断サービスの普及を妨げています。

多くの人はSTD、特に気づかないうちに感染している無症候性感染に関連するリスクを知らないです。このような認識不足は、特に自分がリスクにさらされていると認識していないような集団における検査率の低さにつながっています。例えば、CDCによると、米国では5人に1人近くがSTDに感染しているが、検査を受けないために診断されないままです。特に、クラミジアや淋病のような感染症では、症状が現れないことが多いです。

検査の必要性を認識していても、汚名を着せられることを恐れて性病検査を避ける人も多いです。これは、性の健康に関する議論がタブー視されている保守的な社会では特に顕著です。例えばインドでは、文化的規範が性的健康に関するオープンな会話を妨げており、その結果、検査率が低くなっています。Indian Journal of Public Health誌の調査によると、調査対象となった若者の50％以上が、社会的スティグマを恐れて、医学的アドバイスや性病検査を受けることに消極的でした。

目次

第1章 市場イントロダクションと範囲

  • 報告書の目的
  • 調査範囲と定義
  • 調査範囲

第2章 エグゼクティブの洞察と重要なポイント

  • 市場のハイライトと戦略的ポイント
  • 主な動向と将来の予測
  • 製品タイプ別
  • 病気の種類別
  • 診断テストの種類別
  • エンドユーザー別
  • 地域別

第3章 市場力学

  • 影響要因
    • 促進要因
      • 性感染症の自己診断の進歩
    • 抑制要因
      • 認識と教育の限界
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と著名な企業
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • 新興スタートアップ企業と主要イノベーター
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格市場力学

第5章 性感染症（STD）診断薬市場、製品タイプ別

  • 機器
  • 消耗品
  • ソフトウェア

第6章 性感染症（STD）診断薬市場、疾病タイプ別

  • クラミジア
  • 性器ヘルペス
  • 淋病
  • B型肝炎
  • HIV/エイズ
  • ヒトパピローマウイルス（HPV）
  • 梅毒
  • その他

第7章 性感染症（STD）診断薬市場、診断テストの種類別

  • 分子検査
  • 血清学的検査
  • ポイントオブケア（PoC）テスト
  • その他

第8章 性感染症（STD）診断薬市場、エンドユーザー別

  • 病院
  • 専門クリニック
  • 診断検査室
  • ホームケア設定
  • その他

第9章 性感染症（STD）診断薬市場、地域別、市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第10章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要な市場企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併、買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第11章 企業プロファイル

  • Abbott Laboratories
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
    • SWOT分析
  • Becton, Dickinson, and Company
  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • Hologic, Inc.
  • QIAGEN N.V.
  • Diasorin S.p.A.
  • Seegene Inc.
  • Bosch Healthcare Solutions GmbH

第12章 仮定と調査手法

  • データ収集方法
  • データの三角測量
  • 予測技術
  • データの検証と検証

第13章 付録

目次
Product Code: CD1785

The global Sexually Transmitted Diseases (STD) diagnostics market reached US$ 10.6 billion in 2024 and is expected to reach US$ 19.4 billion by 2033, growing at a CAGR of 7.1% during the forecast period 2025-2033.

Sexually Transmitted Diseases (STD) diagnostics refers to the medical processes and technologies used to detect, identify and confirm the presence of sexually transmitted infections (STIs) in individuals. These diseases are primarily transmitted through sexual contact and can be caused by bacteria, viruses, or parasites. STD diagnostics encompasses a wide range of laboratory tests, clinical evaluations and screening methods to detect infections in their early stages, even before symptoms appear, allowing for timely treatment and reducing the risk of transmission to others.

The demand for sexually transmitted diseases (STD) diagnostics is driven by a variety of factors, ranging from increasing awareness of sexual health to advancements in diagnostic technology. For instance, according to WHO estimates, 374 million new cases of one of the four STIs trichomoniasis (156 million), gonorrhea (82 million), syphilis (7.1 million), and chlamydia (129 million) occurred in 2020. An estimated 300 million women are infected with HPV, the main cause of anal and cervical cancer in males who have sex with men. These rising STDs increase the demand for STD diagnostics.

Market Dynamics: Drivers & Restraints

Rising advancements in STD self-diagnostics

The rising advancements in STD self-diagnostics are significantly driving the growth of the sexually transmitted diseases (STD) diagnostics market and are expected to drive the market over the forecast period. Self-testing kits for STDs allow individuals to test at home without the need for a healthcare professional, making the process more convenient and private. This trend has been particularly important in reducing the stigma associated with STD testing.

For instance, in August 2024, Nova Scotia is going to offer free at-home tests for sexually transmitted infections is an important step toward reducing some barriers to vital sexual health care, says the head of the provincial AIDS coalition.

Additionally, in June 2023, LifeCell International launched test kits that allow patients to collect cell swabs and tissue samples in the privacy of their homes that can then be used for detecting Human Papillomavirus (HPV) which causes cervical cancer in women and sexually transmitted infections like syphilis or gonorrhea.

Modern self-diagnostic tests are designed to provide rapid results, which is a significant driver in the market. Users can get test results in 20 minutes to 1 hour, making it more attractive for those seeking immediate answers. For instance, OraQuick offers a rapid HIV test that delivers results in 20 minutes with no need for laboratory equipment. The speed and ease of these tests contribute to their growing popularity, as individuals are more likely to use tests that provide quick feedback.

Limited awareness and education

Limited awareness and education are significant barriers to the growth of the sexually transmitted diseases (STD) diagnostics market. Despite advances in diagnostic technologies and an increasing range of testing options, insufficient understanding of the importance of STD testing and a lack of education about sexual health have hindered the widespread adoption of diagnostic services.

Many individuals are unaware of the risks associated with STDs, especially asymptomatic infections that can go unnoticed. This lack of awareness leads to low testing rates, especially in populations who might not perceive themselves as being at risk. For instance, according to the CDC, nearly 1 in 5 people in the U.S. are living with an STD, but many remain undiagnosed because they do not seek testing. This is particularly common with infections like chlamydia and gonorrhea, which often present with no symptoms.

Many individuals avoid STD testing due to fear of being stigmatized, even if they are aware of the need for testing. This is particularly true in conservative societies where discussions about sexual health are taboo. For instance, in India, cultural norms discourage open conversations about sexual health, which results in lower testing rates. According to a study by the Indian Journal of Public Health, over 50% of young people surveyed were unwilling to seek medical advice or testing for STDs due to fear of social stigma.

Segment Analysis

The global sexually transmitted diseases (STD) diagnostics market is segmented based on product type, disease type, diagnostic test type, end-user and region.

Disease Type:

The chlamydia segment is expected to dominate the sexually transmitted diseases (STD) diagnostics market share

Chlamydia is one of the most common STDs globally, particularly affecting young adults and adolescents. The Centers for Disease Control and Prevention (CDC) estimates that over 1.8 million new cases of chlamydia are reported annually in the United States alone, making it the most frequently reported STD in the country.

Chlamydia is often asymptomatic, particularly in women, leading to high rates of undiagnosed cases. This makes regular testing crucial, especially among sexually active individuals who may not be aware they are infected. As a result, the demand for routine screening and diagnostic tests increases. Thus, many market players are advancing STD diagnostics for chlamydia testing.

For instance, in May 2024, Sherlock Bio started testing its over-the-counter fast test for identifying STIs including chlamydia, with its plans to sell it by the middle of 2025. In order to compare the accuracy of their CRISPR-based test to widely used lab tests for chlamydia, the business intends to enlist 2,500 sexually active volunteers at 20 research locations around the United States.

Because Chlamydia is highly treatable with antibiotics, early detection and treatment are key to preventing long-term health complications. Many health authorities, including the CDC and the U.S. Preventive Services Task Force (USPSTF), recommend routine screening for Chlamydia for sexually active women under the age of 25 and for individuals in high-risk groups.

Geographical Analysis

North America is expected to hold a significant position in the sexually transmitted diseases (STD) diagnostics market share

North America, especially the United States, has one of the highest rates of sexually transmitted diseases globally. The Centers for Disease Control and Prevention (CDC) reports that more than 2.5 million cases of chlamydia, gonorrhea, and syphilis were diagnosed in the United States between 2020 to 2021. The high incidence of STDs in this region drives the demand for diagnostic tests.

The U.S. has also seen significant challenges with HIV, a key part of the STD landscape. According to HIV.gov, more than 1.2 million Americans are currently living with HIV and many more are at risk of HIV infection. According to the CDC, around 38,000 people in the U.S. are diagnosed with HIV annually, contributing to the demand for regular HIV testing and diagnostics.

North America benefits from strong public health policies that promote regular STD testing, early diagnosis, and treatment. The CDC and other organizations run numerous programs aimed at increasing awareness and access to STD diagnostics. For instance, the "Get Yourself Tested" (GYT) campaign, which encourages young people to get tested for STDs, has significantly increased awareness and testing uptake, particularly among sexually active youth. This initiative has led to a greater demand for diagnostic services and kits.

North America leads in the adoption of advanced diagnostic technologies for STDs. Technologies such as at-home diagnostic kits, rapid diagnostic tests and point-of-care tests are widely used across the region due to their accuracy, ease of use, and quick results.

For instance, in August 2023, the iHealth Labs, Inc. (iHealth) Home Collection Kit for HIV and syphilis testing was released. In the privacy of their own home, anybody over the age of 18 can get a blood sample for testing for syphilis and HIV (I, II, and P24 antigen) using the FDA-approved solution. They can mail the sample to the lab with a pre-paid overnight label and receive accurate and private results in as little as two days. As the STD issue in the United States grew, iHealth responded by launching the first home collection solution in the STD OTC test category.

Asia-Pacific is growing at the fastest pace in the sexually transmitted diseases (STD) diagnostics market

The Asia-Pacific region, home to more than 4.5 billion people, has seen an alarming rise in the incidence of sexually transmitted diseases. According to the World Health Organization (WHO), Asia accounts for a significant percentage of global STD cases. In China, India, and Thailand, the incidence of STDs like chlamydia, gonorrhea, and syphilis is increasing, especially among young people and high-risk groups.

For instance, according to the National Institute of Health (NIH), globally, there are 376 million new cases of four curable STDs (chlamydia, gonorrhea, syphilis, and trichomoniasis) each year, with a significant portion occurring in Asia. In India, syphilis and chlamydia are among the most common STDs, leading to an increased need for diagnostic tests.

Over the past decade, there has been a growing awareness of sexual health issues, including the importance of STD testing, in many parts of Asia. This is primarily driven by global health campaigns, educational initiatives, and increased media coverage of STDs and HIV/AIDS prevention. For instance, In India, public health campaigns, such as those run by the India HIV/AIDS Alliance and Population Foundation of India, have been instrumental in spreading awareness about STDs and HIV, encouraging people to get tested, leading to more frequent testing and demand for diagnostic services.

Additionally, several governments in the Asia-Pacific region have recognized the importance of combating STDs and are investing in prevention, education, and diagnostic services. The Indian government, for instance, has launched the National AIDS Control Programme (NACP), which offers free testing and treatment for HIV, syphilis, and other STDs in many public health centers.

Competitive Landscape

The major global players in the sexually transmitted diseases (STD) diagnostics market include Abbott Laboratories, Becton, Dickinson, and Company, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Hologic, Inc., QIAGEN N.V., Diasorin S.p.A., Seegene Inc., Bosch Healthcare Solutions GmbH and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global sexually transmitted diseases (STD) diagnostics market report delivers a detailed analysis with 70 key tables, more than 70 visually impactful figures, and 188 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Disease Type
  • 2.5. Snippet by Diagnostic Test Type
  • 2.6. Snippet by End-User
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Advancements in STD Self-Diagnostics
    • 3.1.2. Restraints
      • 3.1.2.1. Limited Awareness and Education
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Sexually Transmitted Diseases (STD) Diagnostics Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Instruments*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Consumables
  • 5.4. Software

6. Sexually Transmitted Diseases (STD) Diagnostics Market, By Disease Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 6.1.2. Market Attractiveness Index, By Disease Type
  • 6.2. Chlamydia*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Genital Herpes
  • 6.4. Gonorrhea
  • 6.5. Hepatitis B
  • 6.6. HIV/AIDS
  • 6.7. Human papillomavirus (HPV)
  • 6.8. Syphilis
  • 6.9. Others

7. Sexually Transmitted Diseases (STD) Diagnostics Market, By Diagnostic Test Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 7.1.2. Market Attractiveness Index, By Diagnostic Test Type
  • 7.2. Molecular Tests*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Serologic Tests
  • 7.4. Point-of-Care (PoC) Tests
  • 7.5. Others

8. Sexually Transmitted Diseases (STD) Diagnostics Market, By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Specialty Clinics
  • 8.4. Diagnostic Laboratories
  • 8.5. Homecare Settings
  • 8.6. Others

9. Sexually Transmitted Diseases (STD) Diagnostics Market, By Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
      • 9.2.7.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Brazil
      • 9.4.7.2. Argentina
      • 9.4.7.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. Abbott Laboratories*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
    • 11.1.5. SWOT Analysis
  • 11.2. Becton, Dickinson, and Company
  • 11.3. F. Hoffmann-La Roche Ltd.
  • 11.4. Bio-Rad Laboratories, Inc.
  • 11.5. Thermo Fisher Scientific Inc.
  • 11.6. Hologic, Inc.
  • 11.7. QIAGEN N.V.
  • 11.8. Diasorin S.p.A.
  • 11.9. Seegene Inc.
  • 11.10. Bosch Healthcare Solutions GmbH

LIST NOT EXHAUSTIVE

12. Assumption and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us